MCID: PDT014
MIFTS: 38

Pediatric Ependymoma

Categories: Cancer diseases, Genetic diseases, Neuronal diseases

Aliases & Classifications for Pediatric Ependymoma

MalaCards integrated aliases for Pediatric Ependymoma:

Name: Pediatric Ependymoma 12 15
Childhood Ependymoma 12
Familial Ependymoma 74

Classifications:



External Ids:

Disease Ontology 12 DOID:5509
NCIt 51 C8578
UMLS 74 C1851584

Summaries for Pediatric Ependymoma

MalaCards based summary : Pediatric Ependymoma, also known as childhood ependymoma, is related to ependymoma and benign ependymoma. An important gene associated with Pediatric Ependymoma is MEN1 (Menin 1), and among its related pathways/superpathways are Amoebiasis and Small cell lung cancer. The drugs Carboplatin and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 77 Pediatric ependymomas are similar in nature to the adult form of ependymoma in that they are thought to... more...

Related Diseases for Pediatric Ependymoma

Diseases related to Pediatric Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 ependymoma 30.9 MEN1 RELA
2 benign ependymoma 10.6
3 malignant glioma 9.8
4 glioma 9.8
5 intestinal neuroendocrine benign tumor 9.7 BCAT1 MEN1
6 malignant ependymoma 9.6 ERCC5 LOXL3 RELA
7 small intestine neuroendocrine neoplasm 9.6 BCAT1 MEN1

Graphical network of the top 20 diseases related to Pediatric Ependymoma:



Diseases related to Pediatric Ependymoma

Symptoms & Phenotypes for Pediatric Ependymoma

GenomeRNAi Phenotypes related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.61 LOXL3
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.61 BCAT1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.61 BCAT1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.61 BCAT1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 9.61 BCAT1 LOXL3
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.61 BCAT1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.61 BCAT1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.61 BCAT1
9 Downregulation of NFkappaB pathway GR00313-A 8.62 MEN1 RELA

MGI Mouse Phenotypes related to Pediatric Ependymoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.73 ERCC5 FBXW7 LAMA2 LOXL3 MEN1 RELA
2 digestive/alimentary MP:0005381 9.72 ERCC5 FBXW7 LOXL3 MEN1 RELA
3 craniofacial MP:0005382 9.67 FBXW7 LAMA2 LOXL3 MEN1
4 immune system MP:0005387 9.63 BCAT1 ERCC5 FBXW7 LAMA2 MEN1 RELA
5 liver/biliary system MP:0005370 9.26 ERCC5 FBXW7 MEN1 RELA
6 mortality/aging MP:0010768 9.1 ERCC5 FBXW7 LAMA2 LOXL3 MEN1 RELA

Drugs & Therapeutics for Pediatric Ependymoma

Drugs for Pediatric Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
2
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
3
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
4
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
6
Temozolomide Approved, Investigational Phase 3,Phase 1,Phase 2 85622-93-1 5394
7
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
8
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
9
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
10
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
11
Ondansetron Approved Phase 3 99614-02-5 4595
12
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
13
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
15
Valproic Acid Approved, Investigational Phase 2, Phase 3,Phase 1 99-66-1 3121
16
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6 774
17
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
19
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
20 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
21 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
23 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
24 Vitamin B9 Phase 3,Phase 2,Phase 1,Not Applicable
25 Folate Phase 3,Phase 2,Phase 1,Not Applicable
26 Folic Acid Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
27 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
29 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
30 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
31 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
32 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
33 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
34 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable
35 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
36 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
37 Keratolytic Agents Phase 3,Phase 2
38 Podophyllotoxin Phase 3,Phase 2 518-28-5
39 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
40 Antiemetics Phase 3,Phase 1
41 Emetics Phase 3
42 BB 1101 Phase 3,Phase 2,Phase 1
43 Peripheral Nervous System Agents Phase 3,Phase 1
44 Autonomic Agents Phase 3,Phase 1
45 GABA Agents Phase 2, Phase 3,Phase 1
46 Anticonvulsants Phase 2, Phase 3,Phase 1
47 Neurotransmitter Agents Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
48 Central Nervous System Depressants Phase 2, Phase 3,Phase 1
49 Psychotropic Drugs Phase 2, Phase 3,Phase 1
50 Tranquilizing Agents Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 114)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
2 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
3 An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma Recruiting NCT02265770 Phase 2, Phase 3 16 weeks of VEC + CDDP;VEC + HD-MTX;Chemotherapy + Valproate;VEC;Chemotherapy
4 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Recruiting NCT01096368 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine Sulfate Liposome
5 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
6 Etoposide in Treating Young Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
7 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma Unknown status NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
8 High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
9 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
10 Everolimus for Children With Recurrent or Progressive Ependymoma Completed NCT02155920 Phase 2 Everolimus
11 Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
12 Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Completed NCT00047177 Phase 2 Oxaliplatin
13 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
14 Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
15 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2 Sunitinib Malate
16 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
17 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
18 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
19 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
20 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
21 Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors Completed NCT00003846 Phase 2 carboplatin;cyclophosphamide;thiotepa;vincristine sulfate
22 Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors Completed NCT00003241 Phase 2 phenylacetate
23 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
24 Docetaxel in Treating Children With Recurrent Solid Tumors Completed NCT00002825 Phase 2 docetaxel
25 Vinorelbine in Treating Children With Recurrent or Refractory Cancers Completed NCT00003234 Phase 2 vinorelbine tartrate
26 Lobradimil and Carboplatin in Treating Children With Brain Tumors Completed NCT00019422 Phase 2 carboplatin;lobradimil
27 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
28 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
29 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
30 Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
31 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
32 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors Completed NCT00005955 Phase 2 temozolomide
33 Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors Recruiting NCT02684071 Phase 2 Intra thecal methotrexate;topotecan;cyclophosphamide
34 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Recruiting NCT03526250 Phase 2 Palbociclib
35 Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Recruiting NCT03213704 Phase 2 Larotrectinib;Larotrectinib Sulfate
36 PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03213678 Phase 2 PI3K/mTOR Inhibitor LY3023414
37 Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Recruiting NCT03233204 Phase 2 Olaparib
38 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03213665 Phase 2 Tazemetostat
39 Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03210714 Phase 2 Erdafitinib
40 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Ulixertinib;Vemurafenib
41 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
42 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
43 Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma Active, not recruiting NCT00602667 Phase 2 Induction Chemotherapy;Low-Risk Therapy;High-Risk Therapy;Intermediate-Risk Therapy
44 Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma Terminated NCT01032070 Phase 2 erlotinib;etoposide
45 Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 Terminated NCT01247922 Phase 2 Erlotinib
46 Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma Terminated NCT01088035 Phase 2 Carboplatin
47 TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma Terminated NCT00074334 Phase 1, Phase 2
48 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor Withdrawn NCT00003273 Phase 2 carboplatin;cisplatin;cyclophosphamide;etoposide;leucovorin calcium;methotrexate;temozolomide;thiotepa;vincristine sulfate
49 Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
50 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin

Search NIH Clinical Center for Pediatric Ependymoma

Genetic Tests for Pediatric Ependymoma

Anatomical Context for Pediatric Ependymoma

MalaCards organs/tissues related to Pediatric Ependymoma:

42
Brain, Bone, Bone Marrow, Testes, Spinal Cord, T Cells, Small Intestine

Publications for Pediatric Ependymoma

Articles related to Pediatric Ependymoma:

(show top 50) (show all 57)
# Title Authors Year
1
Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. ( 30811284 )
2019
2
Pediatric ependymoma: current treatment and newer therapeutic insights. ( 30418040 )
2018
3
Limitations of current in vitro models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma. ( 30559935 )
2018
4
Radical, Staged Approach to Extensive Posterior Fossa Pediatric Ependymoma: 3-Dimensional Operative Video. ( 29029279 )
2018
5
Outcomes following proton therapy for pediatric ependymoma. ( 29239262 )
2018
6
Imaging biomarkers of outcome after radiotherapy for pediatric ependymoma. ( 29500084 )
2018
7
Establishment of primary cell culture and an intracranial xenograft model of pediatric ependymoma: a prospect for therapy development and understanding of tumor biology. ( 29774098 )
2018
8
Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. ( 29925527 )
2018
9
Pediatric Ependymoma: A Proteomics Perspective. ( 28387652 )
2017
10
Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma. ( 28437838 )
2017
11
Current Clinical Challenges in Childhood Ependymoma: A Focused Review. ( 28640697 )
2017
12
Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. ( 28733870 )
2017
13
The Pediatric Ependymoma Protein Database (PEPD). ( 29124086 )
2017
14
Pediatric Ependymoma. ( 26503805 )
2016
15
Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma. ( 27104090 )
2016
16
Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. ( 27287856 )
2016
17
Re-irradiation of recurrent pediatric ependymoma: modalities and outcomes: a twenty-year survey. ( 27386327 )
2016
18
Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling. ( 26500028 )
2015
19
Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study. ( 25724157 )
2015
20
Proton beam therapy for pediatric ependymoma. ( 25754294 )
2015
21
Emotional and behavioral functioning after conformal radiation therapy for pediatric ependymoma. ( 24462384 )
2014
22
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. ( 25120190 )
2014
23
Timing of adjuvant radiotherapy and treatment outcome in childhood ependymoma. ( 24167035 )
2014
24
Endoscopic endonasal transclival approach to a ventral pontine pediatric ependymoma. ( 23992235 )
2013
25
PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival. ( 24077346 )
2013
26
mTORC1 activation in childhood ependymoma and response to sirolimus. ( 21076853 )
2011
27
Apurinic/apyrimidinic endonuclease is inversely associated with response to radiotherapy in pediatric ependymoma. ( 21207372 )
2011
28
Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. ( 21627842 )
2011
29
Super-selective basilar artery infusion of bevacizumab and cetuximab for multiply recurrent pediatric ependymoma. ( 22192550 )
2011
30
Telomerase inhibition as a novel therapy for pediatric ependymoma. ( 20184588 )
2010
31
Dosimetric effect of setup motion and target volume margin reduction in pediatric ependymoma. ( 20347495 )
2010
32
Utility of cerebrospinal fluid cytology in newly diagnosed childhood ependymoma. ( 20463607 )
2010
33
Investigating verbal and visual auditory learning after conformal radiation therapy for childhood ependymoma. ( 19783376 )
2010
34
Proton beam therapy following resection for childhood ependymoma. ( 20024657 )
2010
35
New chemotherapy strategies and biological agents in the treatment of childhood ependymoma. ( 19212772 )
2009
36
Pediatric ependymoma: biological perspectives. ( 19531565 )
2009
37
Identification of novel chromosomal abnormalities and prognostic cytogenetics markers in intracranial pediatric ependymoma. ( 18179864 )
2008
38
Intensity-modulated radiation therapy in childhood ependymoma. ( 18258381 )
2008
39
Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. ( 18325681 )
2008
40
EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. ( 18386816 )
2008
41
Primary radiotherapy for childhood ependymoma? ( 17765188 )
2007
42
Contribution of NMR spectroscopy to the differential diagnosis of a recurrent cranial mass 7 years after irradiation for a pediatric ependymoma. ( 16708251 )
2006
43
Salvage treatment for childhood ependymoma after surgery only: Pitfalls of omitting "at once" adjuvant treatment. ( 16863927 )
2006
44
Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. ( 15701279 )
2005
45
Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. ( 15050308 )
2004
46
Childhood ependymoma: a systematic review of treatment options and strategies. ( 12895136 )
2003
47
Cervical subluxation after surgery and irradiation of childhood ependymoma. ( 12006754 )
2002
48
Current management of childhood ependymoma. ( 12108890 )
2002
49
Complex cytogenetic abnormalities including telomeric associations and MEN1 mutation in a pediatric ependymoma. ( 12505253 )
2002
50
Commentary (Paulino): Current Management of Childhood Ependymoma. ( 28776322 )
2002

Variations for Pediatric Ependymoma

Expression for Pediatric Ependymoma

Search GEO for disease gene expression data for Pediatric Ependymoma.

Pathways for Pediatric Ependymoma

Pathways related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.94 LAMA2 RELA
2 10.59 LAMA2 RELA

GO Terms for Pediatric Ependymoma

Biological processes related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 9.33 LOXL3 MEN1 RELA
2 lung development GO:0030324 8.96 FBXW7 LOXL3
3 response to UV GO:0009411 8.62 ERCC5 MEN1

Molecular functions related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding, bridging GO:0030674 8.96 FBXW7 MEN1
2 protein N-terminus binding GO:0047485 8.8 ERCC5 MEN1 RELA

Sources for Pediatric Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....